Corpus ID: 43212414

Duration of action and pharmacokinetics of the oral antidiabetic drug gliquidone in patients with non-insulin-dependent (type 2) diabetes mellitus.

@article{VonNicolai1997DurationOA,
  title={Duration of action and pharmacokinetics of the oral antidiabetic drug gliquidone in patients with non-insulin-dependent (type 2) diabetes mellitus.},
  author={Hubertus Von Nicolai and Rolf Brickl and H Eschey and Andreas Greischel and G. Heinzel and Ellen K{\"o}nig and J. C. Limmer and Eckhard Rupprecht},
  journal={Arzneimittel-Forschung},
  year={1997},
  volume={47 3},
  pages={
          247-52
        }
}
The duration of action and the pharmacokinetics of gliquidone (1-cyclohexyl-3-[[4-[2-(3,4-dihydro-7-methoxy-4,4-dimethyl-1, 3-dioxo-2(1H)-isochinolyl)ethyl]phenyl]-sulfonyl]-urea, AR-DF 26 SE, CAS 33342-05-1, Glurenorm, Beglynor) were investigated in 32 patients with non-insulin-dependent (type 2) diabetes mellitus over 16 h. In a single-blinded cross-over design vs. placebo, one 30 mg tablet gliquidone was administered 15 min before breakfast. Concomitant to the measurement of glucose and… Expand
Simultaneous determination of gliquidone, pioglitazone hydrochloride, and verapamil in formulation and human serum by RP-HPLC.
TLDR
The proposed method is simple and suitable for the simultaneous analysis of active ingredients in dosage forms and human serum and there were no interfering peaks due to the excipients present in the pharmaceutical tablets. Expand
Monitoring of in vitro interaction studies of enalapril with hypoglycemic agents by LC-UV
The coadministration of antihypertensive and antidiabetic drugs is common, as both of these ailments are synergistic to each other and often occur together. In the present paper, we describe in vitroExpand
Simultaneous determination of gliquidone, fexofenadine, buclizine, and levocetirizine in dosage formulation and human serum by RP-HPLC.
TLDR
The proposed method is suitable for the simultaneous analysis of active ingredients in tablet dosage forms and human serum and there was no significant difference between the amount of drug spiked in serum and the amount recovered, and serum did not interfere in simultaneous estimation. Expand
Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus
TLDR
Current T2DM treatment focuses on reducing blood glucose levels via different mechanisms, including nuclear hormone receptors, nucleic acid binding proteins, transcription factors, voltage‐gated K+ channels, glucosidase, G‐protein‐coupled receptors and non‐receptor serine/threonine protein kinase. Expand
Improvement of gliquidone hypoglycaemic effect in rats by cyclodextrin formulations.
TLDR
The findings indicate that cyclodextrin-containing formulations not only provide an onset of hypoglycaemic effect faster than GLI, but also enhance significantly the pharmacological effect due to improved biopharmaceutics. Expand
Gliquidone Contributes to Improvement of Type 2 Diabetes Mellitus Management
TLDR
The metabolism and route of excretion of the drug allow its use in patients who have or may be at risk of diabetic nephropathy, and gliquidone is a sulfonylurea with proven efficacy and good safety and metabolic profiles that is only rarely associated with hypoglycaemia. Expand
Sulfonylureas and Glinides Exhibit Peroxisome Proliferator-Activated Receptor γ Activity: A Combined Virtual Screening and Biological Assay Approach
TLDR
Dual mode of action of sulfonylureas and glinides may open new perspectives for the molecular pharmacology of antidiabetic drugs, and provides evidence that drugs can be designed that target both the sulfonamides and PPARγ, which could increase pancreatic insulin secretion and improve insulin resistance. Expand
The effect of Glurenorm (gliquidone) on lenses and skin in experimental diabetes.
TLDR
The aim of this study was to investigate the effect of administering Glurenorm on the lenses and skins of streptozotocin-induced diabetic rats and found that in the lenses, the gains in turns of reduced NEG and increased GSH may have been offset by the reduction in protein. Expand
Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties.
  • P. Arnouts, D. Bolignano, +4 authors W. van Biesen
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2014
TLDR
The pharmacology of the most widely used glucose-lowering agents is summarized, whether and how it is altered by a reduced renal function, and the recommendations that can be made for their use in patients with different degrees of CKD are discussed. Expand
Sulfonylureas and Glinides Exhibit PPAR γ Activity : A Combined Virtual Screening and Biological Assay Approach *
Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (sulfonylureas, glinides), or target PPARγ improving insulinExpand
...
1
2
3
...